GlassScriptPhysician profile
Isioma Dumebi Wright
NPI 1477094985
$3,854.95
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,969 · 2022: $1,310 · 2023: $554 · 2024: $22.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $754.96 | 2021-2023 | Enbrel, Tavneos |
| Janssen Biotech, INC. | $601.93 | 2021-2023 | Stelara, Simponi, Simponi Aria |
| Abbvie INC. | $389.41 | 2021-2024 | |
| Ucb, INC. | $270.72 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $240.92 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $206.91 | 2021-2023 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $198.32 | 2021-2023 | Orencia |
| Pfizer INC. | $196.35 | 2021-2023 | |
| Horizon Therapeutics Plc | $185.23 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $122.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $112.58 | 2021 | |
| Ani Pharmaceuticals, INC. | $90.72 | 2022 | |
| Genentech USA, INC. | $75.19 | 2021-2022 | |
| Organon LLC | $69.29 | 2021-2023 | Renflexis |
| Pacira Therapeutics, INC. | $54.81 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.22 | 2021-2022 | |
| Depuy Synthes Sales INC. | $32.97 | 2021 | |
| Hikma Pharmaceuticals USA | $30.74 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.80 | 2021 | |
| Mylan Institutional INC. | $24.44 | 2023 | Hulio |
| Lilly USA, LLC | $24.28 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.67 | 2021 | |
| Pharming Healthcare, INC. | $20.73 | 2023 | Ruconest |
| Cumberland Pharmaceuticals, INC. | $18.58 | 2021 | |
| Radius Health, INC. | $18.08 | 2021 | |
| Arteriocyte Medical Systems, INC. | $13.89 | 2023 | Magellan |
| Eyevance Pharmaceuticals LLC | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isioma Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.